Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Pemmaraju on Spleen Volume Reduction With Pacritinib in Myelofibrosis

June 14th 2023

Naveen Pemmaraju, MD, discusses the importance of introducing pacritinib (Vonjo) to the treatment paradigm for patients with myelofibrosis with low platelet counts.

Jaktinib Reduces Splenomegaly, Improves Symptom Burden in Ruxolitinib-intolerant Myelofibrosis

June 13th 2023

The novel JAK and AVCR1 inhibitor jaktinib demonstrated promising therapeutic activity in patients with myelofibrosis who were intolerant to or progressed on ruxolitinib.

Rusfertide Offers Durable Hematocrit Control in Phlebotomy-Dependent Polycythemia Vera

June 11th 2023

Rusfertide demonstrated freedom from phlebotomy, sustained hematocrit control, and 12-week treatment completion in 69.2% vs 18.5% of patients with phlebotomy-dependent polycythemia vera who received placebo, meeting the primary end point of the phase 2 REVIVE trial.

Ruxolitinib Improves Spleen Volume, TSS in Myelofibrosis Irrespective of Anemia, Transfusion Status

June 10th 2023

Ruxolitinib was found to improve spleen volume and tumor symptom score in patients with myelofibrosis, irrespective of their anemia and transfusion status, according to data from a post-hoc analysis of the phase 3 COMFORT-I and -II trials.

Dr Al-Ali on the Safety and Efficacy of BMS-986158 Plus Ruxolitinib or Fedratinib in Myelofibrosis

June 10th 2023

Haifa Kathrin Al-Ali, MD, discusses the safety and efficacy findings from the dose-escalation portion of the phase 1/2 CA011-023 trial of BMS-986158 in combination with ruxolitinib or fedratinib in patients with intermediate- or high-risk myelofibrosis.

Pelabresib Provides Clinical Benefit in Hydroxyurea-Refractory or Intolerant High-Risk Essential Thrombocythemia

June 9th 2023

Treatment with pelabresib monotherapy led to a 60% confirmed complete or partial hematologic response at any time without incurring grade 4 or 5 treatment-related adverse effects in patients with high-risk essential thrombocythemia refractory or intolerant to hydroxyurea.

Dr Bose on Spleen and Symptom Benefit With Pacritinib in Myelofibrosis

June 6th 2023

Prithviraj Bose, MD, discusses key data on the ability of pacritinib to reduce splenomegaly and disease symptoms in patients with myelofibrosis across the cytopenic spectrum.

Dr Garcia-Manero on Luspatercept in Lower-Risk MDS

June 2nd 2023

Guillermo Garcia-Manero, MD, discusses key efficacy and safety findings from the phase 3 COMMANDS trial (NCT03682536) of luspatercept-aamt (Reblozyl) vs epoetin alfa in patients with lower-risk myelodysplastic syndrome.

Dr Zeidan on Imetelstat in Lower-Risk MDS

June 2nd 2023

Amer Zeidan, MBBS, discusses topline efficacy findings from the IMerge trial of imetelstat in patients with transfusion-dependent lower-risk myelodysplastic syndrome.

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

June 2nd 2023

Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.

Luspatercept Nearly Doubles Likelihood of Transfusion Independence in Lower-Risk MDS

May 25th 2023

Luspatercept-aamt led to a higher rate of sustained transfusion independence compared with erythropoiesis stimulating agents in patients with ESA-naïve, lower-risk myelodysplastic syndrome.

NCCN Guidelines List Ropeginterferon Alfa-2b as Preferred Treatment in Polycythemia Vera

May 24th 2023

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option for patients with high- and low-risk polycythemia vera, irrespective of treatment history.

FDA Approves Avapritinib for Indolent Systemic Mastocytosis

May 22nd 2023

The FDA has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis.

MAJIC-PV Trial Confirms Clinical Benefit of Ruxolitinib in Polycythemia Vera

May 19th 2023

Treatment with ruxolitinib generated superior responses vs treatment with best available therapy in patients with hydroxycarbamide-intolerant or -resistant polycythemia vera, according to findings from the phase 2 MAJIC-PV trial.

Dr Mascarenhas on Ongoing Research in Myelofibrosis

May 18th 2023

John Mascarenhas, MD, discusses ongoing trials and research in myelofibrosis.

Dr Mascarenhas on First-line Treatment Decisions in Myelofibrosis

May 16th 2023

John Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.

ECLIPSE PV Trial Begins Ropeginterferon Alfa-2b Dosing in Polycythemia Vera

May 15th 2023

The first patients have been dosed in the phase 3b ECLIPSE PV trial, which is evaluating an accelerated dosing schedule of ropeginterferon alfa-2b-njft for the treatment of patients with polycythemia vera.

Dr Mascarenhas on the Background of the MANIFEST-2 Trial in Myelofibrosis

May 11th 2023

John Mascarenhas, MD, discusses the background of the phase 3 MANIFEST-2 trial investigating the combination of pelabresib and ruxolitinib vs ruxolitinib plus placebo in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.

Dr Jain on Baseline Differences Across Different Donor Types in Myelofibrosis

May 10th 2023

Tania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.

MANIFEST-2 Study of Pelabresib Plus Ruxolitinib Completes Enrollment in Myelofibrosis

May 9th 2023

Enrollment to the phase 3 MANIFEST-2 trial, which is examining the safety and efficacy of pelabresib plus ruxolitinib vs ruxolitinib alone in patients with JAK inhibitor–naïve myelofibrosis, has completed and topline findings are anticipated by the end of 2023.